Argent Capital Management LLC Has $614,000 Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Argent Capital Management LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,841 shares of the biopharmaceutical company’s stock after purchasing an additional 3,339 shares during the period. Argent Capital Management LLC’s holdings in Halozyme Therapeutics were worth $614,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in HALO. Skandinaviska Enskilda Banken AB publ bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $49,000. GAMMA Investing LLC raised its position in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 350 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $57,000. FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth approximately $65,000. Finally, Park Place Capital Corp increased its stake in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,209 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on HALO shares. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.89.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Up 1.6 %

Shares of NASDAQ:HALO opened at $55.37 on Friday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a market capitalization of $7.04 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 0.40 and a beta of 1.24. The company has a fifty day moving average of $49.75 and a 200-day moving average of $54.07.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.